IN2015DN00345A - - Google Patents
Info
- Publication number
- IN2015DN00345A IN2015DN00345A IN345DEN2015A IN2015DN00345A IN 2015DN00345 A IN2015DN00345 A IN 2015DN00345A IN 345DEN2015 A IN345DEN2015 A IN 345DEN2015A IN 2015DN00345 A IN2015DN00345 A IN 2015DN00345A
- Authority
- IN
- India
- Prior art keywords
- disorders
- compounds
- methods
- obesity
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661710P | 2012-06-19 | 2012-06-19 | |
| PCT/US2013/046483 WO2013192273A1 (en) | 2012-06-19 | 2013-06-19 | Heteroaryl compounds and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00345A true IN2015DN00345A (pt) | 2015-06-12 |
Family
ID=49769319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN345DEN2015 IN2015DN00345A (pt) | 2012-06-19 | 2013-06-19 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9505751B2 (pt) |
| EP (1) | EP2861596B1 (pt) |
| JP (3) | JP6236439B2 (pt) |
| KR (1) | KR20150021120A (pt) |
| CN (1) | CN104583210B (pt) |
| AU (1) | AU2013277258B2 (pt) |
| BR (1) | BR112014031798A2 (pt) |
| CA (1) | CA2874180A1 (pt) |
| HK (1) | HK1203494A1 (pt) |
| IL (1) | IL235909A (pt) |
| IN (1) | IN2015DN00345A (pt) |
| MX (1) | MX2014014751A (pt) |
| NZ (1) | NZ702239A (pt) |
| RU (1) | RU2644558C2 (pt) |
| SG (1) | SG11201408178TA (pt) |
| WO (1) | WO2013192273A1 (pt) |
| ZA (1) | ZA201408856B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3019145A1 (en) | 2016-03-28 | 2017-10-05 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
| EP3856185A1 (en) | 2018-09-28 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Balipodect for treating or preventing autism spectrum disorders |
| JP7443357B2 (ja) | 2018-10-23 | 2024-03-05 | ビーエーエスエフ ソシエタス・ヨーロピア | 三環式の殺有害生物化合物 |
| CN110386897A (zh) * | 2019-08-15 | 2019-10-29 | 上海毕得医药科技有限公司 | 一种4-氟-3-甲基吡啶-2-胺的合成方法 |
| WO2021209265A1 (en) | 2020-04-14 | 2021-10-21 | Basf Se | Tricyclic pesticidal compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2274712B1 (es) * | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| US20090143391A1 (en) * | 2007-11-30 | 2009-06-04 | Norbert Hofgen | Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10 |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| US8481532B2 (en) * | 2008-07-09 | 2013-07-09 | Envivo Pharmaceuticals, Inc. | PDE-10 inhibitors |
| TWI485151B (zh) * | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| TWI487705B (zh) * | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基***衍生物 |
| AU2011258217B2 (en) | 2010-05-26 | 2016-12-15 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
| US8765760B2 (en) * | 2011-01-11 | 2014-07-01 | Sunovion Pharmaceuticals, Inc. | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases |
| WO2012147890A1 (ja) * | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | 新規アゾール誘導体 |
| US8592423B2 (en) * | 2011-06-21 | 2013-11-26 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
| EP3495366A1 (en) | 2011-07-15 | 2019-06-12 | Shionogi & Co., Ltd | Azabenzimidazole derivative having ampk-activating activity |
| EP2763533B1 (en) | 2011-10-06 | 2021-12-29 | Merck Sharp & Dohme Corp. | Triazolyl pde10 inhibitors |
-
2013
- 2013-06-19 AU AU2013277258A patent/AU2013277258B2/en not_active Ceased
- 2013-06-19 US US14/409,866 patent/US9505751B2/en active Active
- 2013-06-19 RU RU2014148110A patent/RU2644558C2/ru not_active IP Right Cessation
- 2013-06-19 BR BR112014031798A patent/BR112014031798A2/pt not_active Application Discontinuation
- 2013-06-19 MX MX2014014751A patent/MX2014014751A/es active IP Right Grant
- 2013-06-19 SG SG11201408178TA patent/SG11201408178TA/en unknown
- 2013-06-19 KR KR1020157001398A patent/KR20150021120A/ko not_active Application Discontinuation
- 2013-06-19 WO PCT/US2013/046483 patent/WO2013192273A1/en active Application Filing
- 2013-06-19 CA CA2874180A patent/CA2874180A1/en not_active Abandoned
- 2013-06-19 EP EP13806923.2A patent/EP2861596B1/en active Active
- 2013-06-19 CN CN201380032220.6A patent/CN104583210B/zh active Active
- 2013-06-19 NZ NZ702239A patent/NZ702239A/en not_active IP Right Cessation
- 2013-06-19 JP JP2015518539A patent/JP6236439B2/ja active Active
- 2013-06-19 IN IN345DEN2015 patent/IN2015DN00345A/en unknown
-
2014
- 2014-11-25 IL IL235909A patent/IL235909A/en active IP Right Grant
- 2014-12-03 ZA ZA2014/08856A patent/ZA201408856B/en unknown
-
2015
- 2015-04-23 HK HK15103938.2A patent/HK1203494A1/xx not_active IP Right Cessation
-
2016
- 2016-10-20 US US15/298,469 patent/US9994590B2/en active Active
-
2017
- 2017-09-12 JP JP2017174559A patent/JP6422542B2/ja active Active
-
2018
- 2018-05-11 US US15/977,166 patent/US10604536B2/en active Active
- 2018-10-16 JP JP2018194979A patent/JP6786566B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013277258B2 (en) | 2017-12-07 |
| CN104583210A (zh) | 2015-04-29 |
| US20150322090A1 (en) | 2015-11-12 |
| BR112014031798A2 (pt) | 2017-06-27 |
| KR20150021120A (ko) | 2015-02-27 |
| JP2018048127A (ja) | 2018-03-29 |
| IL235909A0 (en) | 2015-02-01 |
| IL235909A (en) | 2016-09-29 |
| WO2013192273A1 (en) | 2013-12-27 |
| JP6786566B2 (ja) | 2020-11-18 |
| ZA201408856B (en) | 2017-06-28 |
| RU2014148110A (ru) | 2016-08-10 |
| SG11201408178TA (en) | 2015-01-29 |
| US9994590B2 (en) | 2018-06-12 |
| US9505751B2 (en) | 2016-11-29 |
| US10604536B2 (en) | 2020-03-31 |
| JP2015520238A (ja) | 2015-07-16 |
| US20180258104A1 (en) | 2018-09-13 |
| NZ702239A (en) | 2017-01-27 |
| HK1203494A1 (en) | 2015-10-30 |
| RU2644558C2 (ru) | 2018-02-13 |
| AU2013277258A1 (en) | 2014-12-18 |
| JP6236439B2 (ja) | 2017-11-22 |
| EP2861596A4 (en) | 2015-11-04 |
| US20170037060A1 (en) | 2017-02-09 |
| MX2014014751A (es) | 2015-02-24 |
| EP2861596B1 (en) | 2019-03-20 |
| EP2861596A1 (en) | 2015-04-22 |
| JP6422542B2 (ja) | 2018-11-14 |
| CN104583210B (zh) | 2018-06-01 |
| CA2874180A1 (en) | 2013-12-27 |
| JP2019023225A (ja) | 2019-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX351368B (es) | Compuestos heteroarilo y metodos para utilizarlos. | |
| WO2012096929A3 (en) | Heteroaryl compounds and methods of use thereof | |
| HK1249507A1 (zh) | 用於治療炎性障礙的新化合物及其藥物組合物 | |
| MX2020012825A (es) | Compuestos multiciclicos y metodos de uso de los mismos. | |
| WO2014106238A8 (en) | Heterocyclic compounds and methods of use thereof | |
| EP2827856A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MUSCLE DISEASES | |
| MX367623B (es) | 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3. | |
| HK1202458A1 (en) | Glucokinase activator compositions for the treatment of diabetes | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| HK1215794A1 (zh) | 用於治療疾病的同種異體自噬體富集組合物 | |
| MX2013002118A (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| IN2015DN00345A (pt) | ||
| MX361233B (es) | Inhibidores de hsp90 c-terminales. | |
| HUE036285T2 (hu) | Vegyületek alkalmazásra olyan rendellenességek kezelésében, amelyek javíthatók HDAC gátlása révén | |
| IN2015DN02109A (pt) | ||
| MX2013002119A (es) | Sustituidas-2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas como moduladores de kcnq2/3. | |
| MX2015005312A (es) | Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12. | |
| IN2014KN00849A (pt) | ||
| MX2013002295A (es) | 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| HUE037176T2 (hu) | Olaj-alapú gyógyszerészeti készítmény gasztrointesztinális betegségek kezelésére | |
| GB2519470A (en) | Bicyclic aza compounds as muscarinic M1 receptor agonists | |
| WO2014082738A8 (en) | Heteroquinoline-3-carboxamides as kcnq2/3 modulators | |
| HUE039044T2 (hu) | Gyógyászati kompozíció sclerosis multiplex kezelésére | |
| IN2013MU03838A (pt) | ||
| GB201207359D0 (en) | Compounds for the treatment of metabolic disorders |